About Novartis
We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Access
We are committed to bringing more of our medicines to more people, no matter where they are.
People and Culture
Novartis is building an Inspired, Curious and Unbossed culture.
Latest news
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Novartis confirms Sandoz Spin-off for October 4, 2023
Novartis in Society Integrated Report 2022
In 2022, we continued to reimagine medicine and deliver on our purpose to improve and extend people's lives.
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
Novartis has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.
Environmental, Social and Governance
We have a responsibility and opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
The Novartis Commitment to Patients and Caregivers
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.